Kapur, A., O’Connor-Semmes, R., Hussey, E. K., Dobbins, R. L., Tao, W., Hompesch, M., … Nunez, D. J. (2013). First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacology and Toxicology, 14(1). https://doi.org/10.1186/2050-6511-14-26

Kapur, Anita, Robin O’Connor-Semmes, Elizabeth K. Hussey, Robert L. Dobbins, Wenli Tao, Marcus Hompesch, Glenn A. Smith, et al. “First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.” BMC Pharmacology and Toxicology 14, no. 1 (December 2013). https://doi.org/10.1186/2050-6511-14-26.

Kapur A, O’Connor-Semmes R, Hussey EK, Dobbins RL, Tao W, Hompesch M, et al. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacology and Toxicology. 2013 Dec;14(1).

Kapur, Anita, et al. “First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.” BMC Pharmacology and Toxicology, vol. 14, no. 1, Springer Science and Business Media LLC, Dec. 2013. Crossref, doi:10.1186/2050-6511-14-26.

Kapur A, O’Connor-Semmes R, Hussey EK, Dobbins RL, Tao W, Hompesch M, Smith GA, Polli JW, James Jr CD, Mikoshiba I, Nunez DJ. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacology and Toxicology. Springer Science and Business Media LLC; 2013 Dec;14(1).